GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The company's flagship product, EndoBarrier, is a novel, non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic patients and/or obese patients during the implant period. GI Dynamics currently markets EndoBarrier in select regions in Europe, South America and Australia and is planning near-term commercial expansion into additional European countries. EndoBarrier is not approved for sale in the United States and is considered investigational.Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. Through our patented EndoBarrier platform, GI Dynamics is poised to address one of the largest global healthcare markets. We have significant clinical experience, a highly differentiated product profile, the backing of major investors, including Johnson & Johnson Development Corporation, ATV Associates, Polaris, Domain Associates, Cutlass Capital and Medtronic, Inc., and some of the brightest technical and clinical minds in the industry.